# Change Impact Analysis 0.3.9

## Purpose
Document the safety, verification, QMS, and clinical-readiness impact of the 0.3.9 update relative to 0.3.8.

## Scope
This analysis covers software-readiness documentation, traceability, QMS generators/checkers, and clinical-readiness evidence indexing. It does not claim clinical authorization or completion of preclinical evidence.

## Summary of changed areas
- Concrete traceability matrix expanded to 190 requirements.
- Core readiness documents enriched from placeholder-level content to operational draft content.
- ClinicalGapReport and ExtendedVVReport added to the generated QMS evidence set.
- Disabled-test impact checking added for critical clinical-readiness tests.
- Evidence artifact path validation added for traceability rows.
- Placeholder content checking added for readiness documents and traceability requirements.
- Canada ITA and US IDE readiness checklists improved as structured draft checklists.

## Safety impact
The update reduces the risk of false readiness claims by making missing evidence explicit. It does not close high-severity hazards because independent review, residual-risk acceptance, and protocol-bound HIL evidence remain incomplete.

## Verification impact
The normal build and active CTest lane remain the baseline verification path. The clinical-readiness validation lane is now identified as the lane where critical long/controller tests must be executed or formally justified.

## Documentation impact
RegulatoryPackageDraftReady is improved because required readiness documents now contain operational sections, linked artifacts, linked tests, and missing-evidence statements. PreclinicalEvidenceComplete, ClinicalSubmissionReady, and ClinicalTestReady remain unattained.

## Traceability impact
Traceability evidence quality is improved by linking concrete requirements to subsystem, hazard, risk control, source files, tests, evidence artifacts, verification method/status, reviewer placeholder, and residual-risk statement.

## Residual gaps
- Protocol-bound HIL scenario reports are not yet generated.
- HIL risk coverage matrix artifacts are not yet generated from executed sessions.
- High-severity hazards still require independent review and signed residual-risk acceptance.
- Cybersecurity evidence remains structural until penetration/vulnerability evidence is produced.
- Canada/US clinical submission materials remain draft and require qualified review.

## Readiness conclusion
0.3.9 improves RegulatoryPackageDraftReady and traceability evidence but does not achieve PreclinicalEvidenceComplete, ClinicalSubmissionReady, or ClinicalTestReady.
